Literature DB >> 27532154

Trends in Pneumonia Mortality Rates and Hospitalizations by Organism, United States, 2002-2011(1).

Brandon A Wuerth, John P Bonnewell, Timothy L Wiemken, Forest W Arnold.   

Abstract

Because the epidemiology of pneumonia is changing, we performed an updated, population-based analysis of hospitalization and case-fatality rates for pneumonia patients in the United States. From 2002 to 2011, hospitalization rates decreased significantly for pneumonia caused by pneumococcus and Haemophilus influenzae but increased significantly for Pseudomonas spp., Staphylococcus aureus, and influenza virus.

Entities:  

Keywords:  Staphylococcus aureus; Streptococcus pneumoniae; bacteria; case-fatality rate; hospitalization; influenza; pneumonia; respiratory infections; staphylococci; streptococci

Mesh:

Year:  2016        PMID: 27532154      PMCID: PMC4994371          DOI: 10.3201/eid2209.150680

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


Pneumonia is the leading cause of infection-related deaths in the United States, with potential for severe complications such as respiratory failure and sepsis (). A recent nationwide study noted that prior studies may have overestimated a temporal reduction in mortality rate (). As pneumonia epidemiology has changed, interest in following epidemiologic trends continues, particularly for the various etiologic organisms. Emergence of influenza A(H1N1)pdm09 virus has highlighted the role of influenza viruses as etiologic agents of pneumonia (). The epidemiology of pneumonia is constantly changing because of advances in preventive measures, diagnostic testing, and novel therapies. Although the epidemiology, by organism, of pneumonia in hospital patients was recently clarified (), our study also considered the effects of influenza virus and included regional information. Our objective was to provide an updated population-based analysis of hospitalized pneumonia patients to determine the major etiologic agents and associated hospitalization rates, case-fatality rates, and patient demographic differences (age, sex, and region).

The Study

In a retrospective cohort study, we examined hospitalizations of pneumonia patients using discharge data from the publicly available Nationwide Inpatient Sample (NIS) database (). The University of Louisville Institutional Review Board did not require a review because the project did not meet the common rule definition of human subjects’ research. We completed Healthcare Cost and Utilization Project Data Use Agreement Training. The study included patients >18 years of age discharged with a principal diagnosis of pneumonia according to standards of the International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM). We also included those with a principal diagnosis of sepsis or respiratory failure and a secondary diagnosis of pneumonia. Only ICD-9-CM codes for which the numbers of an organism were substantial were analyzed: pneumococci, Klebsiella spp., Pseudomonas spp., Haemophilus influenzae, Staphylococcus aureus, and influenza virus. We followed US Census Bureau definitions in classifying cases by US region (). The NIS database contains an ≈20% stratified sample of US community hospitals. From that sample, the Agency for Healthcare Research and Quality calculated national estimates by weighting each discharge on the basis of hospital location, teaching status, bed number, and ownership control, relative to all US hospitals, which permitted us to estimate the number of US hospitalizations. For each patient discharged, we recorded age, sex, region, principal and secondary diagnoses (up to 15), and whether patient had died from any cause. Population estimates were obtained from the US Census Bureau (). Primary outcomes were temporal trends in hospitalization and case-fatality rates for pneumonia based on infecting organism as determined by ICD-9 coding. We then calculated the rate for hospitalizations caused by each organism using the number of hospitalizations from the NIS database as the numerator and US Census Bureau population estimates as the denominator. Discharge codes do not specify where the pneumonia was acquired, and although hospitalization rate was used, this does not necessarily indicate community-acquired cases. We calculated the all-cause case-fatality rate for each organism similarly, using the number of deaths. We extracted data from the NIS using SAS version 9.3 (SAS Institute, Inc., Cary, NC, USA) and calculated adjusted odds ratios for age ranges, sex, and region using multivariate logistic regression. Study period differences were determined with the online z test calculator of the Healthcare Cost and Utilization Project (p<0.05 was significant) (). Other descriptive statistics were completed with Excel 2013 (Microsoft Corp., Redmond, WA, USA). S. aureus was the most commonly identified organism that caused pneumonia, at 19.2 cases/100,000 population (Table 1). Pneumococcus and influenza virus were more frequent causes in the Midwest, Klebsiella and Pseudomonas spp. were more frequent causes in the South, and H. influenzae and S. aureus were more frequent agents in the West.
Table 1

Hospitalization rates (hospitalization/100,000 population) for 6 causative agents, by sex and region, United States, 2002–2011

CategoryRate (adjusted odds ratio)
Pneumococcus, n = 379,400Klebsiella spp., n = 109,515Pseudomonas spp., n = 330,302Haemophilus influenzae, n = 80,281Staphylococcus aureus, n = 575,573Influenza virus, n = 270,237
Overall
12.6
3.6
11.0
2.7
19.2
9.0
Sex
M13.0 (1)4.1 (1)12.3 (1)2.7 (1)20.5 (1)8.0 (1)
F
12.3 (0.68)
3.2 (0.57)
9.7 (0.57)
2.6 (0.72)
17.9 (0.64)
10.0 (0.90)
Region
Northeast11.9 (1)3.1 (1)8.8 (1)2.1 (1)15.9 (1)8.8 (1)
Midwest15.1 (1.33)3.1 (1.05)11.5 (1.37)3.3 (1.61)17.7 (1.17)12.8 (1.51)
South12.8 (1.16)4.6 (1.65)13.0 (1.62)2.8 (1.46)22.5 (1.57)9.0 (1.10)
West10.7 (1.32)3.0 (1.48)9.1 (1.55)2.3 (1.64)17.9 (1.71)5.5 (0.90)
Hospitalization rates, based on etiologic agent, changed during the study period (Figure 1). Overall, the rate for pneumonia hospitalizations caused by pneumococcus decreased 23% (p<0.001) and for H. influenzae, 42% (p<0.001). For Klebsiella, the rate increased 35% (p<0.001); for Pseudomonas, 23% (p<0.001); for S. aureus, 23% (p<0.001); and for influenza virus, 132% (p<0.001).
Figure 1

Hospitalization rates (hospitalizations/100,000 population) for patients with pneumonia for 6 causative agents, United States, 2002–2011.

Hospitalization rates (hospitalizations/100,000 population) for patients with pneumonia for 6 causative agents, United States, 2002–2011. Case-fatality rate was highest for pneumonia caused by S. aureus: 15.6 deaths/100 cases (Table 2). Pneumococcal pneumonia, Klebsiella, Pseudomonas, and S. aureus were more frequent in the Northeast, whereas pneumonia caused by H. influenzae and influenza virus was more frequent in the West.
Table 2

All-cause case-fatality rate (deaths/100 cases for 6 causative agents, by sex and region, United States, 2002–2011

Category
Rate (adjusted odds ratio)
Overall case-fatality rates, based on causal agent (Figure 2), decreased for pneumococcus by 18% (p = 0.01), for Pseudomonas spp. by 8% (p = 0.29), for H. influenzae by 3% (p = 0.85), and for S. aureus by 32% (p<0.001). Rates increased for Klebsiella spp. by 13% (p = 0.26); and for influenza virus by 67% (p<0.001). Hospitalization and case-fatality rates by age are shown in Technical Appendix Tables 1, 2.
Figure 2

All-cause case-fatality rate (deaths/100 cases) for patients with pneumonia for 6 causative agents, United States, 2002–2011.

All-cause case-fatality rate (deaths/100 cases) for patients with pneumonia for 6 causative agents, United States, 2002–2011.

Conclusions

We found that, from 2002 to 2011, the hospitalization rates for pneumonia caused by Klebsiella spp., Pseudomonas spp., S. aureus, and influenza virus increased, and those caused by pneumococcus and H. influenzae decreased. The case-fatality rate of influenza virus–caused pneumonia increased, while rates of pneumococcus-caused and S. aureus–caused pneumonia decreased. Hospitalization and case-fatality rates were higher for men (especially elderly) than for women. Our results coincide with those of previous studies, which found that S. aureus, pneumococcus, and Pseudomonas spp. comprised a large percentage of all pneumonia cases (,). Our results also coincide with those of a similar study which used the NIS database during 1993–2011: a decrease in pneumonia caused by Streptococcus spp., H. influenzae, and Pseudomonas spp. and an increase in pneumonia caused by Staphylococcus spp. (). However, our study also examined trends in pneumonia caused by Klebsiella spp. and influenza virus and regional variations. Another study that used similar methods found that adjusted odds ratio of an inpatient death from pneumonia decreased from 2002 to 2005 (). Previous studies also found that male patients >75 years old carried the greatest disease prevalence and considerably greater hospitalization rates (185/10,000 population in 2006) (,). US regional data are limited, and comparable results, based on clinical data, were not found. However, 2 sets of data from the Centers for Disease Control and Prevention (Atlanta, GA, USA) showed the highest incidence of pneumonia in the Midwest and the lowest in the West (,). Drivers of geographic differences could include variations in coding practices between regions and vaccination recommendation adherence (). Known changes in the epidemiology of pneumonia over the study period include the emergence of influenza A(H1N1)pdm09 virus, which caused 60.8 million cases of influenza and 12,469 deaths in 2009–2010 alone (). We found that patients with influenza virus infections had the highest hospitalization rate during 2009. Many previous studies excluded influenza because it likely represents a separate clinical entity and the hospitalization rate can be difficult to interpret using calendar years (because early or late influenza seasons can skew yearly trends) (,). Our study was limited by its reliance on ICD-9-CM coding to identify cases, potentially allowing misclassification. ICD-9-CM coding is based on discharge data, so determining whether the patient was diagnosed with pneumonia at admission or during hospitalization is not possible. Thus, we could not differentiate between community- or hospital-acquired cases. In addition, we did not examine unspecified cases of pneumonia that did not include an etiologic organism, the most commonly used pneumonia code. Decreases in hospitalization rates and case-fatality rates could be explained by improved outpatient management or increased rates of vaccination. Last, case-fatality rates were calculated by using deaths during the inpatient stay and not beyond, because coding did not permit 30-day outcomes. In conclusion, knowing which etiologic agents are increasing or have the highest case-fatality rate is critical because treatment options and prognosis vary by organism, and resources must be allocated accordingly. Knowing patient demographic characteristics for each organism is also essential, to clarify the populations at greatest risk.

Technical Appendix

Tables showing hospitalization rate per 100, 000 population by organism and age and all-cause case-fatality rate per 100 population by organism and age, United States, 2002–2011.
  10 in total

1.  The influence of age and gender on the population-based incidence of community-acquired pneumonia caused by different microbial pathogens.

Authors:  Félix Gutiérrez; Mar Masiá; Carlos Mirete; Bernardo Soldán; J Carlos Rodríguez; Sergio Padilla; Ildefonso Hernández; Gloria Royo; Alberto Martin-Hidalgo
Journal:  J Infect       Date:  2006-01-10       Impact factor: 6.072

2.  Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009-April 2010).

Authors:  Sundar S Shrestha; David L Swerdlow; Rebekah H Borse; Vimalanand S Prabhu; Lyn Finelli; Charisma Y Atkins; Kwame Owusu-Edusei; Beth Bell; Paul S Mead; Matthew Biggerstaff; Lynnette Brammer; Heidi Davidson; Daniel Jernigan; Michael A Jhung; Laurie A Kamimoto; Toby L Merlin; Mackenzie Nowell; Stephen C Redd; Carrie Reed; Anne Schuchat; Martin I Meltzer
Journal:  Clin Infect Dis       Date:  2011-01-01       Impact factor: 9.079

3.  Mortality reduction among pneumonia patients still substantial despite the impact of coding changes.

Authors:  Gregory W Ruhnke; Marcelo Coca Perraillon; David M Cutler
Journal:  Am J Med       Date:  2013-03       Impact factor: 4.965

4.  Association of diagnostic coding with trends in hospitalizations and mortality of patients with pneumonia, 2003-2009.

Authors:  Peter K Lindenauer; Tara Lagu; Meng-Shiou Shieh; Penelope S Pekow; Michael B Rothberg
Journal:  JAMA       Date:  2012-04-04       Impact factor: 56.272

5.  Accuracy of administrative data for identifying patients with pneumonia.

Authors:  Dominik Aronsky; Peter J Haug; Charles Lagor; Nathan C Dean
Journal:  Am J Med Qual       Date:  2005 Nov-Dec       Impact factor: 1.852

6.  Regional variations in diagnostic practices.

Authors:  Yunjie Song; Jonathan Skinner; Julie Bynum; Jason Sutherland; John E Wennberg; Elliott S Fisher
Journal:  N Engl J Med       Date:  2010-05-12       Impact factor: 91.245

7.  Microbial etiology of community-acquired pneumonia in the adult population of 4 municipalities in eastern Finland.

Authors:  C Jokinen; L Heiskanen; H Juvonen; S Kallinen; M Kleemola; M Koskela; M Leinonen; P R Rönnberg; P Saikku; M Stén; A Tarkiainen; H Tukiainen; K Pyörälä; P H Mäkelä
Journal:  Clin Infect Dis       Date:  2001-03-23       Impact factor: 9.079

8.  Deaths: leading causes for 2010.

Authors:  Melonie Heron
Journal:  Natl Vital Stat Rep       Date:  2013-12-20

9.  Health care-associated pneumonia and community-acquired pneumonia: a single-center experience.

Authors:  Scott T Micek; Katherine E Kollef; Richard M Reichley; Nareg Roubinian; Marin H Kollef
Journal:  Antimicrob Agents Chemother       Date:  2007-08-06       Impact factor: 5.191

10.  Trends in pathogens among patients hospitalized for pneumonia from 1993 to 2011.

Authors:  Sean B Smith; Gregory W Ruhnke; Curtis H Weiss; Grant W Waterer; Richard G Wunderink
Journal:  JAMA Intern Med       Date:  2014-11       Impact factor: 21.873

  10 in total
  12 in total

Review 1.  The Unexpected Impact of Vaccines on Secondary Bacterial Infections Following Influenza.

Authors:  Amber M Smith; Victor C Huber
Journal:  Viral Immunol       Date:  2017-11-17       Impact factor: 2.257

2.  Budget Impact of Omadacycline for the Treatment of Patients with Community-Acquired Bacterial Pneumonia in the United States from the Hospital Perspective.

Authors:  Kenneth LaPensee; Rohit Mistry; Thomas Lodise
Journal:  Am Health Drug Benefits       Date:  2019-02

3.  Estimates of the Health and Economic Burden of Pneumococcal Infections Attributable to the 15-Valent Pneumococcal Conjugate Vaccine Serotypes in the USA.

Authors:  Kwame Owusu-Edusei; Arijita Deb; Kelly D Johnson
Journal:  Infect Dis Ther       Date:  2022-01-27

4.  Influenza virus infections among patients attending emergency department according to main reason to presenting to ED: A 3-year prospective observational study during seasonal epidemic periods.

Authors:  Enrique Casalino; Stephanie Antoniol; Nadhira Fidouh; Christophe Choquet; Jean-Christophe Lucet; Xavier Duval; Benoit Visseaux; Laurent Pereira
Journal:  PLoS One       Date:  2017-08-16       Impact factor: 3.240

5.  Excess pneumonia and influenza hospitalizations associated with influenza epidemics in Portugal from season 1998/1999 to 2014/2015.

Authors:  Emanuel Rodrigues; Ausenda Machado; Susana Silva; Baltazar Nunes
Journal:  Influenza Other Respir Viruses       Date:  2018-01       Impact factor: 4.380

6.  IL-33-mediated Eosinophilia Protects against Acute Lung Injury.

Authors:  Paulette A Krishack; Maile K Hollinger; Timothy G Kuzel; Trevor S Decker; Tyler J Louviere; Cara L Hrusch; Anne I Sperling; Philip A Verhoef
Journal:  Am J Respir Cell Mol Biol       Date:  2021-05       Impact factor: 6.914

7.  Effect of albumin administration on outcomes in hypoalbuminemic patients hospitalized with community-acquired pneumonia (ALBUCAP): a prospective, randomized, phase III clinical controlled trial-a trial protocol.

Authors:  Alexander Rombauts; Gabriela Abelenda-Alonso; Antonella Francesca Simonetti; Guillermo Verdejo; Yolanda Meije; Lucia Ortega; Mercedes Clemente; Jordi Niubó; Yolanda Ruiz; Carlota Gudiol; Cristian Tebé; Sebastian Videla; Jordi Carratalà
Journal:  Trials       Date:  2020-08-20       Impact factor: 2.279

8.  Attributable burden in patients with carbapenem-nonsusceptible gram-negative respiratory infections.

Authors:  Ying P Tabak; Anita Sung; Gang Ye; Latha Vankeepuram; Vikas Gupta; Eilish McCann
Journal:  PLoS One       Date:  2020-02-21       Impact factor: 3.240

9.  Contributing Factors to the Clinical and Economic Burden of Patients with Laboratory-Confirmed Carbapenem-Nonsusceptible Gram-Negative Respiratory Infections.

Authors:  Eilish McCann; Anita H Sung; Gang Ye; Latha Vankeepuram; Ying P Tabak
Journal:  Infect Drug Resist       Date:  2020-03-09       Impact factor: 4.003

10.  A multiplex polymerase chain reaction assay for antibiotic stewardship in suspected pneumonia.

Authors:  Chiagozie Pickens; Richard G Wunderink; Chao Qi; Haritha Mopuru; Helen Donnelly; Kimberly Powell; Matthew D Sims
Journal:  Diagn Microbiol Infect Dis       Date:  2020-08-16       Impact factor: 2.803

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.